ELAN PHARM
BiotechELAN PHARM is a biotechnology company focused on Neurology.
ELAN PHARM's Key Drugs
ELAN PHARM's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
ELAN PHARM's Recent FDA Approvals
New NDA/BLA approvals for ELAN PHARM over the last two years — novel drugs only, excluding generics and label supplements.
ELAN PHARM's Therapeutic Areas
ELAN PHARM's approved drugs and pipeline span 1 therapeutic area, led by Neurology, across 1 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
ELAN PHARM's Top Competitors
ELAN PHARM's closest competitors by therapeutic-area and drug-target overlap include Pfizer, AbbVie, and Eli Lilly. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
ELAN PHARM Pipeline Snapshot
ELAN PHARM has 2 active clinical programs from ClinicalTrials.gov — 0 Phase 3, 0 Phase 2 and 2 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Neurology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2000-12-08
- Latest
- 2021-03-10
- Applications
- 2